A citation-based method for searching scientific literature

Joon Young Hur, Bo Mi Ku, Joon Ho Shim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. In Vivo 2020
Times Cited: 3







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
86
66

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
103
66

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8
66


Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
122
66

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
115
66

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
313
66

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis,[...]. Clin Cancer Res 2019
62
66

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
402
66

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Alexis B Cortot, Zoulika Kherrouche, Clotilde Descarpentries, Marie Wislez, Simon Baldacci, Alessandro Furlan, David Tulasne. J Natl Cancer Inst 2017
37
66

Chemotherapy advances in small-cell lung cancer.
Bryan A Chan, Jermaine I G Coward. J Thorac Dis 2013
77
33

Update on the optimal use of bortezomib in the treatment of multiple myeloma.
Meera Mohan, Aasiya Matin, Faith E Davies. Cancer Manag Res 2017
33
33

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Ajai Chari, Attaya Suvannasankha, Joseph W Fay, Bertrand Arnulf, Jonathan L Kaufman, Jainulabdeen J Ifthikharuddin, Brendan M Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo,[...]. Blood 2017
285
33

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Nicholas R Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Kolinsky, Gareth J Williams, Pinaki Bose, Susan P Lees-Miller. Cancers (Basel) 2020
33
33


Selinexor for the treatment of multiple myeloma.
Klaus Podar, Jatin Shah, Ajai Chari, Paul G Richardson, Sundar Jagannath. Expert Opin Pharmacother 2020
17
33

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil. Int J Mol Sci 2019
55
33

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Andrew Spencer, Simon Harrison, Jeffrey Zonder, Ashraf Badros, Jacob Laubach, Krystal Bergin, Amit Khot, Todd Zimmerman, Dharminder Chauhan, Nancy Levin,[...]. Br J Haematol 2018
35
33


The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu. Signal Transduct Target Ther 2019
108
33

New Modalities for Challenging Targets in Drug Discovery.
Eric Valeur, Stéphanie M Guéret, Hélène Adihou, Ranganath Gopalakrishnan, Malin Lemurell, Herbert Waldmann, Tom N Grossmann, Alleyn T Plowright. Angew Chem Int Ed Engl 2017
143
33

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
Jayaprakash K Nair, Jennifer L S Willoughby, Amy Chan, Klaus Charisse, Md Rowshon Alam, Qianfan Wang, Menno Hoekstra, Pachamuthu Kandasamy, Alexander V Kel'in, Stuart Milstein,[...]. J Am Chem Soc 2014
478
33

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
Michel de Weers, Yu-Tzu Tai, Michael S van der Veer, Joost M Bakker, Tom Vink, Daniëlle C H Jacobs, Lukas A Oomen, Matthias Peipp, Thomas Valerius, Jerry W Slootstra,[...]. J Immunol 2011
582
33



Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
P Kapoor, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, D Dingli, J R Mikhael, V Roy, R A Kyle, P R Greipp,[...]. Leukemia 2011
84
33

Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.
Xingdong Chen, Jeffrey Gole, Athurva Gore, Qiye He, Ming Lu, Jun Min, Ziyu Yuan, Xiaorong Yang, Yanfeng Jiang, Tiejun Zhang,[...]. Nat Commun 2020
71
33

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng,[...]. Lancet Oncol 2019
59
33

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Chad C Bjorklund, Jian Kang, Michael Amatangelo, Ann Polonskaia, Mark Katz, Hsiling Chiu, Suzana Couto, Maria Wang, Yan Ren, Maria Ortiz,[...]. Leukemia 2020
48
33

The emerging role of oncolytic virus therapy against cancer.
Luke Russell, Kah-Whye Peng. Chin Clin Oncol 2018
56
33

Targeting the androgen receptor in triple-negative breast cancer: current perspectives.
Alain Mina, Rachel Yoder, Priyanka Sharma. Onco Targets Ther 2017
31
33

Breast cancer brain metastases: the last frontier.
José Pablo Leone, Bernardo Amadeo Leone. Exp Hematol Oncol 2015
65
33

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Tiffany A Traina, Kathy Miller, Denise A Yardley, Janice Eakle, Lee S Schwartzberg, Joyce O'Shaughnessy, William Gradishar, Peter Schmid, Eric Winer, Catherine Kelly,[...]. J Clin Oncol 2018
173
33

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.
Anishka D'Souza, Darcy Spicer, Janice Lu. J Hematol Oncol 2018
19
33

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Joshua D Hansen, Matthew Correa, Mark A Nagy, Matt Alexander, Veronique Plantevin, Virginia Grant, Brandon Whitefield, Dehua Huang, Timothy Kercher, Roy Harris,[...]. J Med Chem 2020
29
33



Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Andrea Sassen, Justine Rochon, Peter Wild, Arndt Hartmann, Ferdinand Hofstaedter, Stephan Schwarz, Gero Brockhoff. Breast Cancer Res 2008
111
33



Emerging therapies for multiple myeloma.
Klaus Podar, Yu-Tzu Tai, Teru Hideshima, Sonia Vallet, Paul G Richardson, Kenneth C Anderson. Expert Opin Emerg Drugs 2009
33
33

Induction Therapy for Newly Diagnosed Multiple Myeloma.
Barry Paul, Brea Lipe, Enrique M Ocio, Saad Z Usmani. Am Soc Clin Oncol Educ Book 2019
12
33

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Renata Duchnowska, Sibylle Loibl, Jacek Jassem. Cancer Treat Rev 2018
24
33

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot,[...]. Lancet 2019
323
33

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
E K Mai, U Bertsch, J Dürig, C Kunz, M Haenel, I W Blau, M Munder, A Jauch, B Schurich, T Hielscher,[...]. Leukemia 2015
87
33

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Winston W Tan, Jacob B Allred, Alvaro Moreno-Aspitia, Donald W Northfelt, James N Ingle, Matthew P Goetz, Edith A Perez. Clin Breast Cancer 2016
21
33

Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, Anna Lau, Michelle P Turner, Kathy S Albain. NPJ Breast Cancer 2018
16
33

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.
Nobuyuki Horita, Masaki Yamamoto, Takashi Sato, Toshinori Tsukahara, Hideyuki Nagakura, Ken Tashiro, Yuji Shibata, Hiroki Watanabe, Kenjiro Nagai, Miyo Inoue,[...]. Sci Rep 2015
42
33

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu Steven Xu, Philippe Moreau, Saad Z Usmani, Sagar Lonial, Andrzej Jakubowiak, Albert Oriol, Amrita Krishnan, Joan Bladé, Man Luo, Yu-Nien Sun,[...]. Adv Ther 2020
2
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.